AHA Coding Clinic® for HCPCS - 2021 Quarter 3; For Your Information
Revocation of EUA for COVID-19 monoclonal antibody treatment
Revocation of emergency use authorization (EUA) for the COVID-19 monoclonal antibody therapy bamlanivimab and deletion of HCPCS codes M0239 and Q0239 effective July 2021 The Centers for Medicare & Medicaid Services (CMS) listed new HCPCS codes M0239 and Q0239 that were established effective November 9, 2020, for bamlanivimab to track and pay appropriately for monoclonal antibodies used to treat COVID-19. The codes were added to the January 2021 I/OCE with their effective dates set to the dates they were authorized by the FDA. Effective April 16, 2021, the U.S. Food and Drug Administration revoked the emergency use...
Subscribe or sign in to view the full article.
Article Overview
This article explains a federal regulatory change affecting COVID-19 monoclonal antibody treatment coding and reimbursement administration. It is aimed at coding, billing, and reimbursement professionals who need to understand how FDA authorization changes can affect HCPCS maintenance and Medicare claims processing. The discussion covers the timing of the EUA revocation, the related CMS code update, and the impact on code availability in the relevant quarterly edit system.
Why This Topic Matters
Changes in authorization status can affect whether specific treatment codes remain active for Medicare billing and tracking. This update helps stakeholders align coding workflows with current federal policy and claims-processing edits.
What You Will Learn
- How FDA authorization changes can affect billing code maintenance
- How CMS updates related HCPCS codes when treatment status changes
- The general relationship between EUA revocation and Medicare claims processing edits
- Which federal organizations are involved in the code update process
Who Should Read This
- Medical coders
- Billing staff
- Revenue cycle professionals
- Compliance staff
- Practice administrators
- Hospital outpatient coding teams
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com